Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of the Childrens Hospital of Philadelphia, Philadelphia, PA, speaks about his excitement over the CRB-401 study (NCT02658929), which uses anti-BCMA CAR T-cell agent bb2121 for refractory multiple myeloma (MM). BCMA targeting represents a new area for CAR T-cells, and Dr Grupp emphasizes the importance of these positive findings in MM and other hematological malignancies.
